Research context
A melanocortin receptor agonist; approved uses and access vary by country.
Regulatory note: Verify local laws, product approval and professional guidance before any human use. This profile is not a recommendation for use.
Melanocortin medicine
PT-141 (Bremelanotide)
A melanocortin receptor agonist; approved uses and access vary by country.
21 connected records21 graded citations0 external identifiers
Evidence map
Claims linked to original records.
Evidence levels describe study design. They do not by themselves establish safety or effectiveness.
Yuvaraaj VK, Sharma N
Comprehensive characterization of bremelanotide acetate and its degradants by LC-HRMS/MS and predicting epimerization through computational modelling.
pubmed
Merlino F, Jia L, Boccino I, Carotenuto A, Tammaro F, Santoro F, Thompson PE, Grieco P
Goldilocks-Inspired Design of Mid-Size Macrocycles for Selective Targeting of Human Melanocortin Receptors.
pubmed
Ashour AM
Clinical trial evidence on emerging pharmacological therapies for hypoactive sexual desire disorder in women: a systematic review and analysis of completed studies registered on ClinicalTrials.gov.
pubmed 2026
Guptan N, Simon JA
Quantification of "Mercy Sex" in Heterosexual Women.
pubmed 2026
Tran L, Nguyen TD, Gad AG, Shaaban E, Tai TH, Tram NT, Nguyen Khanh Tran H, Le MT, Huy NT
FDA-Approved Drugs Containing D-Amino Acids: A Historical and Developmental Perspective.
pubmed 2026
Pfaus JG, Balon R
Should Bremelanotide Be Considered for the Treatment of Sexual Arousal and Desire Disorders in Men?
pubmed
Mihulka O, Curran M, Narasimhan RM, Moore JF, Rojas KE
Strategies for Treating Sexual Health Concerns After Breast and Gynecologic Cancer.
pubmed 2026
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an optional Open-label Extension to evaluate the efficacy of bremelanotide (BMT), administered subcutaneously (SC) on an as needed basis for the treatment of HSDD (with or without decreased arousal) in premenopausal females.
1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
clinicaltrials 2014
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an optional Open-label Extension to evaluate the efficacy of bremelanotide (BMT), administered subcutaneously (SC) on an as needed basis for the treatment of HSDD (with or without decreased arousal) in premenopausal females.
2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
clinicaltrials 2015
This trial is designed to evaluate the efficacy and safety of 3 fixed dose levels of bremelanotide, administered subcutaneously on an as-needed basis under conditions of home use, for the treatment of female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD), or mixed FSAD/HSDD...
Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder
clinicaltrials 2011
This 8 week at home study is designed to explore efficacy endpoints and evaluate the safety of intranasal Bremelanotide in women with Female Sexual Arousal Disorder. Efficacy will be assessed vs. a parallel placebo group.
Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)
clinicaltrials 2007
C.S. Brown · Elsevier BV
An Effect on the Subjective Sexual Response in Premenopausal Women with Sexual Arousal Disorder by Bremelanotide (PT-141), a Melanocortin Receptor Agonist
crossref 2007
ABSTRACT Introduction Melanocortins affect multiple physiological responses, including sexual behaviors. Bremelanotide is a synthetic peptide melanocortin analog of α-melanocyte-stimulating hormone that is an agonist at melanocortin receptors MC3R and MC4R. Aim To evaluate a single intranasal dose of bremelanotide for potential effects on physiological and...
An Effect on the Subjective Sexual Response in Premenopausal Women with Sexual Arousal Disorder by Bremelanotide (PT-141), a Melanocortin Receptor Agonist
crossref 2006
· Springer Berlin Heidelberg
Bremelanotide
crossref
Anita Clayton · Morressier
Efficacy of Bremelanotide in The RECONNECT Studies
crossref 2017
· Cambridge University Press
BREMELANOTIDE
crossref 2024
· Cambridge University Press
Bremelanotide
crossref 2020
Swati PT · Jaypee Brothers Medical Publishers (P) Ltd.
How do Magnets Act
crossref 2004
Mitchell T. Harberson, Jennifer W. Hill · Springer International Publishing
Bremelanotide
crossref 2021
Mitchell T. Harberson, Jennifer W. Hill · Springer International Publishing
Bremelanotide
crossref 2021
Mavrych V, Shypilova I, Bolgova O
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.
pubmed 2026
Connected data hub
Records with source provenance.
Reviewed records carry an admin-reviewed badge. Automated records link back to the provider for independent checking.
Publication
8 recordspubmedAutomated import
Clinical trial evidence on emerging pharmacological therapies for hypoactive sexual desire disorder in women: a systematic review and analysis of completed studies registered on ClinicalTrials.gov.
Ashour AM
pubmedAutomated import
Quantification of "Mercy Sex" in Heterosexual Women.
Guptan N, Simon JA
pubmedAutomated import
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.
Mavrych V, Shypilova I, Bolgova O
pubmedAutomated import
Strategies for Treating Sexual Health Concerns After Breast and Gynecologic Cancer.
Mihulka O, Curran M, Narasimhan RM, Moore JF, Rojas KE
pubmedAutomated import
FDA-Approved Drugs Containing D-Amino Acids: A Historical and Developmental Perspective.
Tran L, Nguyen TD, Gad AG, Shaaban E, Tai TH, Tram NT, Nguyen Khanh Tran H, Le MT, Huy NT
pubmedAutomated import
Comprehensive characterization of bremelanotide acetate and its degradants by LC-HRMS/MS and predicting epimerization through computational modelling.
Yuvaraaj VK, Sharma N
pubmedAutomated import
Goldilocks-Inspired Design of Mid-Size Macrocycles for Selective Targeting of Human Melanocortin Receptors.
Merlino F, Jia L, Boccino I, Carotenuto A, Tammaro F, Santoro F, Thompson PE, Grieco P
pubmedAutomated import
Should Bremelanotide Be Considered for the Treatment of Sexual Arousal and Desire Disorders in Men?
Pfaus JG, Balon R
Scholarly Work
9 recordscrossrefAutomated import
BREMELANOTIDE
· Cambridge University Press
crossrefAutomated import
Bremelanotide
Mitchell T. Harberson, Jennifer W. Hill · Springer International Publishing
crossrefAutomated import
Bremelanotide
Mitchell T. Harberson, Jennifer W. Hill · Springer International Publishing
crossrefAutomated import
Bremelanotide
· Cambridge University Press
crossrefAutomated import
Efficacy of Bremelanotide in The RECONNECT Studies
Anita Clayton · Morressier
crossrefAutomated import
An Effect on the Subjective Sexual Response in Premenopausal Women with Sexual Arousal Disorder by Bremelanotide (PT-141), a Melanocortin Receptor Agonist
C.S. Brown · Elsevier BV
crossrefAutomated import
An Effect on the Subjective Sexual Response in Premenopausal Women with Sexual Arousal Disorder by Bremelanotide (PT-141), a Melanocortin Receptor Agonist
ABSTRACT Introduction Melanocortins affect multiple physiological responses, including sexual behaviors. Bremelanotide is a synthetic peptide melanocortin analog of α-melanocyte-stimulating hormone that is an agonist at melanocortin receptors MC3R and MC4R. Aim To evaluate a single intranasal dose of...
crossrefAutomated import
How do Magnets Act
Swati PT · Jaypee Brothers Medical Publishers (P) Ltd.
crossrefAutomated import
Bremelanotide
· Springer Berlin Heidelberg
Clinical Trial
4 recordsclinicaltrialsAutomated import
2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an optional Open-label Extension to evaluate the efficacy of bremelanotide (BMT), administered subcutaneously (SC) on an as needed basis for the treatment of HSDD (with or without decreased arousal)...
clinicaltrialsAutomated import
1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an optional Open-label Extension to evaluate the efficacy of bremelanotide (BMT), administered subcutaneously (SC) on an as needed basis for the treatment of HSDD (with or without decreased arousal)...
clinicaltrialsAutomated import
Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder
This trial is designed to evaluate the efficacy and safety of 3 fixed dose levels of bremelanotide, administered subcutaneously on an as-needed basis under conditions of home use, for the treatment of female sexual arousal disorder (FSAD), hypoactive...
clinicaltrialsAutomated import
Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)
This 8 week at home study is designed to explore efficacy endpoints and evaluate the safety of intranasal Bremelanotide in women with Female Sexual Arousal Disorder. Efficacy will be assessed vs. a parallel placebo group.
Live discovery
Latest research signals
Live results from PubMed, ClinicalTrials.gov and UniProt. These may not yet have been reviewed or stored in the Data Hub.
Recent PubMed records
Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review.PMID 42862021 · 2026 Sep 30Comprehensive characterization of bremelanotide acetate and its degradants by LC-HRMS/MS and predicting epimerization through computational modelling.PMID 42485063 · 2026 Aug 20Goldilocks-Inspired Design of Mid-Size Macrocycles for Selective Targeting of Human Melanocortin Receptors.PMID 42340853 · 2026 Aug 13Clinical trial evidence on emerging pharmacological therapies for hypoactive sexual desire disorder in women: a systematic review and analysis of completed studies registered on ClinicalTrials.gov.PMID 42254382 · 2026Quantification of "Mercy Sex" in Heterosexual Women.PMID 42144994 · 2026Registered clinical studies
1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire DisorderNCT02333071 · COMPLETED2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire DisorderNCT02338960 · COMPLETEDBremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire DisorderNCT01382719 · COMPLETEDReviewed UniProt records
Responsible use of information
Fitzbio provides educational and research reference material. It does not diagnose, prescribe or replace advice from a qualified healthcare professional.